Roche celebrates groundbreaking for state-of-the-art research and development building in Basel

• New CHF 500 million investment will accelerate drug development at Basel site

• Building 12 will serve as an interface between early research and development and will be completed by 2029

• Roche has invested around eight billion Swiss francs in its Swiss sites since 2015 – Building 12 is a further commitment to the Basel site

Jürg Erismann, Site Head of Roche Basel/Kaiseraugst, emphasises the strategic importance of the project: “Building 12 is an essential part of our long-term vision for the Basel site. The investment of CHF 500 million is a clear commitment to Basel and underlines Roche's long-term commitment to this research location and to Switzerland.”

Building 12 will consolidate various research and development functions that were previously spread across the site. By bringing these teams together in a single, state-of-the-art facility, Roche will promote collaboration, foster forward-looking initiatives, and further increase research efficiency. The exterior design of the 72-meter-tall Building 12 mirrors that of Building 6, the research and development center that opened last year, ensuring it blends with the existing high-rise structure of the campus.

Since 2015, Roche has invested approximately CHF 8 billion into its Swiss sites. Furthermore, Roche has invested CHF 33 billion in research and development in Switzerland since 2015, resulting in a total investment of over CHF 40 billion over the last decade (2015 to 2024). Given that Roche generates only about 1% of its total sales in Switzerland, the Swiss location therefore benefits disproportionately from the Group's total investment.

Facts about Building 12:

• Investment: approx. CHF 500 million

• Building area: 32,200 m²

• Building height: 72 m

• Number of floors: 15

• Number of workplaces: approx. 450

• Project period: Q1 2023 - Q4 2029

• Groundbreaking: 29 October 2025

• Completion: Q4 2029

• Architects: Herzog & de Meuron, Basel